Study of PH3 for the Prevention of Osteoporosis in Postmenopausal Women

Inclusion criteria

• Women 40-60 years of age.
• Must be postmenopausal (0.5~5 years post cessation of menses) or ovariectomized or hysterectomy women who have documented elevated Follicle Stimulating Hormone FSH (>30mIU/ml) with low serum estradiol (<20 pg/ml).
• The lumbar vertebral BMD T-score is between -1and -2.5 SD.
• The body mass index (BMI) is between 19 and 29 kg/m2.
• Completed informed consent and signed informed consent form.

Exclusion criteria

• Have diseases which may affect bone metabolism, e. g., hyper-or hypocalcemia, hyperthyroidism, osteogenesis imperfecta, malignancy, chronic gastrointestinal disease, extensive Paget's disease, alcoholism, and renal or hepatic impairment.
• Has taken drug therapy for osteoporosis within the previous six months (excluding calcium supplements) prior to this study.
• Chronic or continued use of hormone replacement drugs or medications that may affect bone calcium metabolism, for example, phosphate-binding antacids, many diuretics, adrenal or anabolic steroids, heparin, anticonvulsants, fluoride in excess of 1 mg/day and supplements of vitamin D or A in excess of RDAs.
• Vitamin D deficiency (1, 25-dihydroxyvitamin D is lower than the normal range of: 25.1 pg/mL ~ 66.1 pg/mL).
• Patients with fracture history.
• Patients who can not promise to keep from taking stimulant drinks (for example, coffee, tea, alcoholic drink, and Coke) that may cause loss of bone calcium, during the study period.